GNPX Genprex
WatchlistGenprex News
12 Health Care Stocks Moving In Friday's After-Market Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) stock rose 15.4% to $0.3 during Friday's after-market session. Today's trading volume for this security ended up closing at 6.8 million shares, which is 1
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
Genprex to Present at Upcoming H.C. Wainwright Conference
Genprex to Present at Upcoming September Investor Conference
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, Sept. 7, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gen
GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know
Genprex Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAllarity Therapeutics (NASDAQ:ALLR) shares increased by 31.5% to $2.13 during Wednesday's after-market session. Allarity Therapeutics's trading volume hit 1.3 million shares by close, accountin
Genprex Appoints Regulatory Expert as It Drives Clinical Programs Forward
4 Big Analyst Cuts: Premier Downgraded at Piper Sandler Following Q4 Earnings
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs
Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small
Genprex Granted FDA Orphan Drug Designation for REQORSA(R) for SCLC
Genprex Wins FDA Orphan Drug Designation for Lead Asset
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA Immunogene Therapy for the Treatment of Small Cell Lung Cancer
ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the Acclaim-3 clinical trial in the fourth quarter of 2023 AUSTIN, Texas, Aug. 10, 2023 /PRNewswire/ -- Genprex,
Genprex Gets FDA Orphan Drug Designation For Quaratusugene Ozeplasmid For Treatment Of Small Cell Lung Cancer
Genprex Gets FDA Orphan Drug Designation For Quaratusugene Ozeplasmid For Treatment Of Small Cell Lung Cancer
Genprex's Third Fast Track Designation Validates REQORSA(R)'s Potential
Genprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company on a mission to develop life-changing therapies for patients with cancer and diabetes, recently received a patent in China Genprex China Patent No: 201780076886.X from the China National Intellectual Property Administration. The granted patent broadly covers the use of the company's drug candidate REQORSAI immunogene therapy in combination with PD-1 antibodies, such as KeytrI(R), to treat cancers
Genprex Inc. Closes on $7.5M Registered Direct Offering
Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas, July 21, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient
Genprex Inc. Announces $7.5M Registered Direct Offering
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersenVVeno Medical (NASDAQ:NVNO) shares moved upwards by 29.4% to $4.71 during Wednesday's regular session. Trading volume for enVVeno Medical's stock is 595.4K as of 13:30 EST. This is 1331.0% of